Sanofi to Invest €1.3B in New BioCampus Frankfurt Insulin Facility by 2029

Aug 1, 2024, 06:28 PM

French drugmaker Sanofi has announced plans to invest 1.3 billion euros ($1.40 billion) in a new insulin production facility at its existing site in Frankfurt Höchst, Germany, part of the BioCampus. The new facility, expected to be completed by 2029, aims to enhance the production of Sanofi's insulin brand, Lantus. This investment is part of Sanofi's broader strategy to expand its manufacturing capacity, which includes a recent commitment of $1.1 billion to increase capacity at three sites in France. The new Frankfurt insulin plant is anticipated to create hundreds of jobs in Germany, adding to the site's current workforce of over 4,000 employees and over 500 jobs in France.